The mainstay of breast cancer treatment remains surgical resection, but the addition of systemic chemotherapy can reduce the risk of relapse ([@bib37]). Neoadjuvant chemotherapy has been shown to have equivalent rates of disease-free survival (DFS) and overall survival (OS) when compared to adjuvant chemotherapy ([@bib23]). The benefit to neoadjuvant chemotherapy is the increased rate of breast-conserving surgery ([@bib20]; [@bib35]). The adjuvant breast and bowel project has shown that patients receiving neoadjuvant chemotherapy who had a complete pathologic response have a significantly improved DFS and OS. In the adjuvant breast and bowel project, the percentage of patients with a complete pathologic response was as much as 26% depending on the chemotherapy regimen ([@bib35]), and according to a meta-analysis, rates of complete pathologic response ranged from 4 to 29% ([@bib23]). However, as many as 21% of patients in the adjuvant breast and bowel project had no clinical response ([@bib35]).

It is also known that rates of response to neoadjuvant chemotherapy depend significantly on the biomarker profiles of the primary breast cancer ([@bib32]; [@bib11]). Therefore, the ability to reliably identify the biomarker profile (phenotype) within the breast cancer may allow better selection of patients for neoadjuvant chemotherapy and selection of individualised therapy regimens, building the pillars for personalised medicine. For example, luminal A tumours have been shown to be less chemosensitive than other phenotypes of breast cancer, with some studies showing that adjuvant chemotherapy did not provide survival benefit for patients ([@bib31]). Some studies have suggested that patients with luminal A breast cancer when treated with paclitaxel benefit only if the proliferation index is low. In addition, in patients with HER2+tumours, treatment with trastuzumab has shown to be beneficial with increases in complete response and event-free survival ([@bib31]). These are just a few examples of how regimens targeted at tumour phenotype have proven beneficial.

This is particularly relevant in breast cancer due to its high level of heterogeneity ([@bib38]; [@bib2]). Core biopsies are currently used to investigate cancer biomarkers, but only a small portion of the tumour can be sampled, which is not necessarily the predominant nor the most aggressive area, raising the possibility of under-estimating the most aggressive phenotype of cancer ([@bib22]). The sampling error of core biopsies can lead to treating patients who may not benefit from neoadjuvant chemotherapy or administering a chemotherapy regimen that is not tailored to the patient.

In this study, we explored the ability of contrast-enhanced breast \[^18^F\] FDG positron emission tomography magnetic resonance (PET/MR) to identify the phenotype of breast cancer.

Materials and methods
=====================

Patient enrolment
-----------------

This Health Insurance Portability and Accountability Act compliant retrospective study was approved by the institutional review board. Patients gave written informed consent for study enrolment, including the possibility of using their imaging, genetics, and clinical data in future evaluations.

The authors had full control of the data and information submitted for publication and did not receive any financial support for this research study.

Inclusion criteria: (a) recent diagnosis of invasive ductal carcinoma, (b) biopsy of the primary breast cancer with available biomarkers, (c) absence of treatment, (d) age older than 18 years, (e) whole-body contrast-enhanced 18F FDG PET/MR that included breast MR perfusion, (f) breast cancer diameter of at least 20 mm, and (g) whole-body staging follow-up of ⩾12 months. We decided to choose a very conservative minimum size criterion, a tumour diameter of at least 20 mm, 5 times as thick as our DWI sequence, to improve the robustness of ADC measurements, to reduce the risk of averaging areas of possible geometric distortion, and to reduce the risk of partial volume effect being 10 times as big as the PET voxel size.

Exclusion criteria included: (a) pregnancy; (b) blood glucose levels \>140 mg dl^−1^ (7.77 mmol l^−1^); (c) inadequate PET/MR images; (d) contraindication to MR imaging; and (e) inability to tolerate being in the PET/MR imager.

Pathology
---------

Core needle biopsies were performed under ultrasound guidance by a radiologist with more than 15 years of experience (OAC). A pathology technologist fixed them in 10% neutral buffered formalin (NBF) at the time of biopsy. All patients who underwent mastectomy after completion of neoadjuvant chemotherapy had the mastectomy specimens sent to the department of pathology immediately after resection. They were cut in 5 mm thick slices and fixed in NBF for 6--48 h. Haematoxylin and eosin and immunohistochemistry (IHC) studies were evaluated by one pathologist (ML) with more than 12 years of experience in breast pathology. Staining for oestrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor-2 (HER2) was performed as per AAP guidelines ([@bib45]; [@bib14]).

The Benchmark Ultra staining module (Ventana Medical Systems Inc, Tucson, AZ, USA) was employed for IHC assessment of ER, PR, and HER2. Paraffin fixed specimens were placed on positively charged slides after being cut into 5 *μ*m-thick slices. For assessment of ER and PR, slices were incubated at 70 °C for 2 h; for HER2 assessment they were air-dried overnight at room temperature. The following primary monoclonal antibodies (Ventana Medical Systems Inc) were used: for ER, CONFIRM anti-ER (SP1, 1 *μ*g ml^−1^); for PR, CONFIRM anti-PR (1E2, 1 *μ*g ml^−1^); and for HER2, PATHWAY anti-HER2/neu (4B5, 6 *μ*g ml^−1^). The pre-diluted monoclonal Clone 30-9 (Ventana Medical Systems Inc) was used for assessment of antigen Ki-67 (Ki-67) expression, and a count of more than 500 neoplastic cells was employed to measure the fraction of proliferating cells (KI-67 positive).

PET/MR protocol
---------------

All patients fasted for at least 6 h before imaging. Blood glucose levels were assessed with a blood glucometer (OneTouch Vita; LifeScan, Milpitas, CA, USA) before imaging to ensure it was \<140 mg dl^−1^ (7.77 mmol l^−1^).

Positron emission tomography magnetic resonance imaging began 85±24 min after FDG injection (mean dose, 4.44 MBq per kilogram of body weight, range, 370--400 MBq). This incubation time is explained by the legal and IRB mandatory requirement of obtaining a standard of care PET-CT 60 min after FDG injection before acquiring any PET-MR. However, the reconstruction software automatically corrects for the delay between the time of FDG injection and that of PET data acquisition for each bed position.

Positron emission tomography magnetic resonance studies were acquired with a Biograph mMR imager (Siemens Healthcare). They included a whole-body PET/MR acquisition and a dedicated breast MR perfusion protocol. The whole-body PET/MR was performed with a 16-channel head and neck surface coil and three or four 12-channel body coils (depending on patient height) combined to form a multichannel whole-body coil by using total imaging matrix technology. Positron emission tomography magnetic resonance was acquired with the patient supine, from the mid-thigh towards the head. Positron emission tomography data were automatically attenuation corrected with attenuation maps generated from the two-point Dixon sequence. This portion of the exam was used only for measuring the SUV~max~ of the primary breast cancer; therefore, in [Table 1](#tbl1){ref-type="table"} we provide only the pertinent parameters. After this acquisition, the patient was placed prone, and the dedicated breast study, including DWI and MR perfusion, was acquired with a dedicated four-channel breast coil. The scanner automatically generated both the ADC maps and the subtracted post-contrast images at each time point. The pertinent parameters are outlined in [Table 1](#tbl1){ref-type="table"}.

Image analysis
--------------

Images were analysed in consensus, by a nuclear medicine physician (AS) with 33 years of experience and by a radiologist with 17 years of experience in MR, on a dedicated workstation (SyngoVia, Siemens Healthcare). The automated PET encircling function from the mMR-general layout workflow was used to include the entire FDG avid tumour and obtain the SUV~max~. For measuring the ADCmean, the same layout workflow was used; the entire tumour was manually encircled on the DWI and ADC images. Spatial correlation with subtracted MR perfusion images was employed to improve lesion identification, when necessary. For the MR perfusion analysis, a Tofts-based commercially available software (Tissue4D, Siemens Healthcare) was employed. The entire tumour was manually encircled on the earliest contrast-enhanced subtracted image set that best demonstrated the cancer against the adjacent normal tissues. Then, the following measurements were obtained: mean volume transfer coefficient (Ktrans), mean flux rate constant (Kep), mean extracellular volume ratio (Ve), and the initial area under the curve (iAUC).

Statistical analysis
--------------------

The possible association between PET-MR biomarkers (ADC~mean~, Ktrans~mean~, Kep~mean~, Ve~mean~, iAUC, and SUV~max~) and IHC expression of ER, PR, HER2, and Ki67 was assessed using two-sample Student\'s *t*-tests, with a 0.05 significance level. We matched our PET/MR biomarkers against IHC expression of ER, PR, HER2, and Ki-67 on the biopsies from all patients. The biomarkers were also matched against a cohort that included the expression of the markers in the entire tumour in those with residual cancer at mastectomy plus the biopsy in those with a pathologic complete response at mastectomy.

The utility of biomarkers for predicting tumour phenotype was assessed by one-way ANOVA. Tumour phenotype prediction models were fit using linear discriminant analysis with leave-one-out cross-validation. The statistical significance of fitted models was assessed by permutation analysis. Two analyses were performed. First, we predicted biopsy phenotype for all patients. We also fit a second model, using full-tumour data when available, and biopsy data for patients who did not have detectable residual cancer. The statistical significance of the number of correct predictions was determined by simulation, conditional on the observed frequencies of subtypes in the data. Data were analysed using R (Version 3.1.0; [@bib34]), with the MASS library extension ([@bib44]).

Results
=======

We recruited 49 consecutive newly diagnosed non-operated patients with IDC (all women, age 18--79) between March 2012 and February 2013. Twenty-eight of these were excluded for the following reasons: 19 for non-availability of histology biomarkers and 9 for having a cancer \<20 mm in maximal diameter. Therefore, our final population consisted of 21 patients. They underwent neoadjuvant chemotherapy that consisted of 5-Fluorouracil, epirubicin, and cyclophosphamide (FEC) in 16, FEC plus paclitaxel in 3, and paclitaxel in 2.

For all these 21 patients, core biopsy specimens were available. Entire tumour specimens from mastectomy were available for 16/21 patients; due to complete response to neoadjuvant chemotherapy in 5/21, no residual tumour was available. ER, PR, HER2, and Ki67 were assessed for 21/21 patients on biopsy specimens, and on 16/21 on the whole excised tumour.

On biopsy specimens, we found 14/21 ER+, 12/21 PR+, 10/21 HER2+, and 12/21 Ki-67 ⩽14% patients ([Table 2](#tbl2){ref-type="table"}). This resulted in 3/21 patients with a luminal A phenotype, 8/21 with a luminal B phenotype, 3/21 with a luminal HER2 phenotype, and 7/21 with a HER2 enriched phenotype ([Table 2](#tbl2){ref-type="table"}).

On whole-tumour assessment in the 16/21 patients with residual tumour after neoadjuvant chemotherapy, we found: 11/16 ER+, 9/16 PR+, 6/16 HER2+, and 10/16 Ki67 ⩽14% tumours ([Table 2](#tbl2){ref-type="table"}). Three of these 16 patients were Ki67\>14% on biopsy but Ki67 ⩽14% on whole-tumour evaluation. In summary, upon entire residual tumour evaluation 5/16 patients had a luminal A phenotype, 5/16 a luminal B phenotype, 1/16 a luminal HER2 phenotype, and 5/16 a HER2 enriched phenotype.

Combining the IHC of residual cancer at mastectomy in 16 cases and that obtained on biopsy in the 5 cases who had complete response, we got these final results: 6/21 luminal A, 5/21 luminal B, 3/21 luminal Her2, and 7/21 Her2 enriched ([Table 2](#tbl2){ref-type="table"}).

Patients generally had high-grade tumours with 0/21 grade 1, 14/21 grade 2, and 7/21 grade 3. Based on biopsy and on entire tumour plus biopsy, for those with complete regression, the same results were obtained when evaluating for expression of ER, PR, and HER2. Both the mean flux rate constant (Kep~mean~) and maximum standard uptake value (SUV~max~) differentiated ER/PR− and ER or PR+ tumours ([Figures 1](#fig1){ref-type="fig"}, [2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"}). Statistically significant higher values of Kep~mean~ (*P*=0.011) and SUV~max~ (*P*=0.005) were found in ER/PR− tumours as compared to ER/PR+ tumours. No other imaging biomarkers were significantly different ([Table 3](#tbl3){ref-type="table"}).

Statistically significant higher values of ADC~mean~ (*P*=0.009), Kep~mean~ (*P*=0.028), and SUV~max~ (*P*=0.046) were measured in HER2 negative compared to HER2-positive tumours ([Figure 2](#fig2){ref-type="fig"} and [Table 3](#tbl3){ref-type="table"}).

As far as Ki67 expression, ADC~mean~ values were statistically significantly lower in Ki67⩽14% compared to Ki67\>14% expression (*P*=0.025 on biopsy, *P*=0.011 on entire cancer plus biopsy; [Table 3](#tbl3){ref-type="table"} and [Figure 3](#fig3){ref-type="fig"}). No other PET-MR biomarkers behaved differently in relation to Ki67 expression.

No grading differences were encountered between core biopsy and whole-cancer specimens. Grade 2 breast cancers had lower Kep~mean~ (*P*=0.036) and lower SUV~max~ (*P*=0.042) than grade 3 tumours ([Table 3](#tbl3){ref-type="table"}). However, since there were no grade 1 tumours in our patients, we could not evaluate the differentiation of all grades.

No other imaging biomarkers showed a statistically significant correlation with breast cancer biomarkers. Specifically, the transfer constant (Ktrans~mean~) was not significantly different for any of the tested molecular expressions.

Upon multivariate analysis utilising Kep~mean~, ADC~mean~, and SUV~max~, we were able to correctly identify the tumour phenotype in 14/21 biopsies (67% *P*=0.001). However, upon cross-validation, PET-MR biomarkers correctly predicted 8/21 phenotypes (38%), and this was not statistically significant (*P*=0.22; [Table 4](#tbl4){ref-type="table"}).

When we explored the capability of the PET-MR biomarkers against the phenotypes obtained from entire cancer specimens from 16 patients plus biopsies from the 5 cases who experienced complete remission, our model was capable of predicting the correct phenotype in 13 out of 21 patients (62% *P*=0.001), and when we cross-validated these results, the model correctly predicted 10 out of 21 cases (48%). These results had statistical significance (*P*=0.04; [Table 4](#tbl4){ref-type="table"}).

Discussion
==========

Utilising a multivariate analysis with (a) SUV~max~, (b) ADC~mean~, and (c) Kep~mean~, we were able to correctly predict the phenotypes of breast cancer in 14/21 cases (67%) compared to biopsy and 13/21 (62%) compared to excision of the whole tumour plus biopsy in the five cases without residual disease at mastectomy. While numerous previous studies have looked at the correlations of PET and MR biomarkers with tumour genotypes and phenotypes, to our knowledge, this is the first study that attempts to predict tumour phenotype based on a multivariate analysis of both PET and MR biomarkers. This could be useful for future patient treatment or help patient selection for neoadjuvant therapy trials since selected therapy is often based on hormone receptor status, HER-2 status, and proliferation rate ([@bib31]).

There was a statistically significant direct correlation of ADC~mean~ with HER2-positive tumours (*P*=0.009), which is in agreement with several previous papers ([@bib21]; [@bib7]; [@bib36]; [@bib30]; [@bib19]). In our population, we found a direct correlation between ADC~mean~ and Ki-67 ⩽14% on biopsy (*P*=0.025) and excision plus biopsy (*P*=0.011). However, published data on ADC and Ki-67 expression in breast cancer are conflicting ([@bib15]; [@bib8]; [@bib10]; [@bib25]; [@bib26]). Specifically, Mori and colleagues showed a correlation of multiple different ADC parameters with Ki-67 at a cutoff of 14%, establishing a threshold cutoff of 1097 × 10^−6^ mm^2^ s^−1^ which was 82% sensitive and 71% specific for Ki-67 proliferation. However, they found that the high proliferation tumours had lower ADC as opposed to our findings where low proliferation tumours had a lower ADC value ([@bib26]). On the other hand, DeFelice and Jeh found no correlation between ADC and Ki-67 expression ([@bib15]; [@bib10]). ADC is influenced by several factors, including grading, with a demonstrated direct correlation between ADC and higher tumour grade G3 ([@bib10]). In our study, the majority of the Ki-67 negative cancers were grade 2, and this might have contributed to the lower ADC observed in the setting of Ki-67 ⩽14%.

There was a statistically significant correlation of a high Kep~mean~ with ER/PR negativity (*P*=0.011 when compared to ER or PR +) and HER-2 positivity (*P*=0.028). Enhancement characteristics have long been of interest in differentiating subtypes and phenotypes of breast cancer. As early as 2003, [@bib40] evaluated breast tumours on the basis of rim enhancement, washout, and early maximal enhancement, demonstrating that there was a correlation with these findings and markers of poor prognosis. More recently, studies have corroborated our findings of a correlation with Kep and Ki-67 proliferation ([@bib17]) and ER negativity ([@bib18]). [@bib18] took the evaluation one step further and showed that triple-negative breast cancers had a higher mean Kep than luminal type breast cancers.

There was a statistically significant correlation of a high SUV~max~ with ER/PR-negative tumours (*P*=0.005) and HER-2 positivity (*P*=0.046). Prior studies have gone as far as to correlate a lower SUV~max~ with an improved DFS ([@bib16]; [@bib3]; [@bib12]) and OS ([@bib3]; [@bib12]). This suggests a link between SUV~max~ and tumour biology and/or phenotype. Several prior studies have shown a correlation with either ER or PR negativity ([@bib41]; [@bib13]; [@bib9]; [@bib16]; [@bib24]; [@bib46]) and HER-2 enriched tumours ([@bib9]) with an elevated SUV~max~.

Several prior studies have attempted to correlate different MR and PET biomarkers with breast cancer phenotypes including a high median ADC with HER-2 enriched tumours ([@bib21]), differences in ADC between multiple phenotypes ([@bib36]; [@bib19]), a low SUV~max~ for luminal A tumours ([@bib24]), and increased SUV~max~ with triple-negative breast cancers ([@bib13]; [@bib46]). While we agree that evaluating for the phenotype of a malignancy is important, rather than comparing the phenotypes by single parameters, we propose evaluating for phenotypes based on a multivariate algorithm. In our analysis, we compared different MR biomarkers and SUV~max~ values with particular receptors, then used a multivariate analysis to determine luminal types based on the receptors exhibited. For example, an ADC value that correlates with HER-2 positivity along with a mean Kep and SUV~max~ which correlate with ER or PR positivity lend itself to a luminal HER-2 tumour.

In our analysis, we were in agreement with the phenotype of breast cancer based on biopsy in 16/21 (67%) cases. However, after cross validation only 8/21 phenotypes (38%) were predicted, and this was not statistically significant (*P*=0.22). However, based on excised specimens in those with residual cancer plus biopsy for those with complete response, we correctly predicted the phenotype in 13 of 21 patients (62%), and these predictions retained statistical significance after cross-validation predicting 10 out of 21 cases (48% *P*=0.004). Although these initial results are encouraging, the prediction rate is still low and they cannot be translated into clinical practice. The incapability to be correct in predicting the remaining cases could be potentially explained by the heterogeneity of the primary breast cancer and by the necessity to rely on biopsy for the 5 cases that experienced complete response after neoadjuvant chemotherapy. In these 5 cases, we had to use the IHC performed on the small biopsied portion of the cancer for the analysis. PET/MR, assessing the entire tumour, can potentially provide a more comprehensive assessment of its biology compared to biopsy, which is limited to a small area of the cancer, not always representative of the entire neoplastic biology.

A significant limitation to our study is the small number of cases. Therefore, our data should be considered as a preliminary investigation. A larger sample size would increase our power for identifying more useful MR and PET biomarkers. Other studies showed a statistically significant correlation between Ki-67 level and SUV~max~ ([@bib6]; [@bib9]; [@bib47]); the lack of correlation in our study might be related to differences in population and/or sample size. Additional biomarkers as supported by a larger study may lead to improved phenotypic identification by imaging. With data from more patients we could build a more reliable and accurate algorithm that could be validated prospectively.

Our findings also relied on regions of interest (ROIs), which included the whole tumour rather than spot ROIs. Spot ROIs may better account for tumour heterogeneity, especially in the case of large tumours. Although PET/MR is capable of providing such spot ROIs, they might need to be checked against the exact same corresponding area within the sliced tumour.

In a study by Arponen and colleagues, they demonstrated that by placing ROIs in the area of the tumour with the lowest ADC they could show a significant correlation with low ADC and axillary lymph node metastases, lymphovascular invasion, and high tumour grade. This was in addition to the correlation that was seen in both whole-tumour ROIs and spot ROIs with low ADC that included PR positivity and stage ([@bib4]). PET/MR derived colour-coded biomarker maps are amenable to a section-by-section analysis to highlight the differences in phenotype expression in different areas of each section, pointing out the most aggressive ones that need to be selectively biopsied. The targeting of biopsies for the areas of the primary breast cancer with more concerning features by MR biomarkers may be a future direction. A comparison between random and targeted biopsies could be evaluated for clinically significant heterogeneity. This likely explains the differences in Ki67 expression between biopsy and surgical pathology that occurred in 3 cases. However, a different response to therapy of different neoplastic clones cannot be completely ruled out as an explanation for this discordance. Evaluation of untreated cancers might overcome this possible limitation. However as per current NCCN guidelines, neoadjuvant chemotherapy is administered to stage IIA, IIB and III cancers that fulfil criteria for breast-conserving surgery except for tumour size ([@bib27]).

This preliminary study does have additional limitations. We used FDG since it is the most commonly clinically available radiopharmaceutical and to make our results potentially verifiable by other groups. Receptor-specific radiopharmaceuticals were not used because they are not widely available. This would have potentially rendered our study irreproducible, more expensive (our study was self-funded), and moreover a single receptor-specific radiopharmaceutical might have highlighted only one feature of the receptor expression profile of the cancers. However, we are aware that other radiopharmaceuticals showed potential to characterise breast cancer better that FDG ([@bib42]; [@bib43]; [@bib39]; [@bib1]; [@bib29]).

Moreover, we acquired PET/MR 85±24 min after FDG injection, instead of the usual incubation period of 60 min. Our longer incubation time is explained by the legal obligation and IRB requirements to perform a standard of care PET-CT at 60 min after FDG injection, before acquiring a PET-MR study. However, it is unlikely that this influenced the FDG values we measured. In fact, the PET-MR reconstruction software, approved for clinical use worldwide, automatically corrects for the delay between the time of FDG injection and the time of PET data acquisition for each bed position. Moreover, several studies have demonstrated comparable SUV values between PET-CT and subsequently acquired PET-MR ([@bib28]; [@bib5]; [@bib33]).

The main technical limitation was the use of a PET/MR compatible body coil for PET attenuation correction. In subsequently acquired patients, including follow-ups on this same cohort, we used a dedicated PET/MR compatible breast coil that was not available at the start of the project. However, to ensure consistency, we preferred not to combine patients acquired with different coils. For a preliminary feasibility study, we believe that the findings of properly identifying the breast cancer phenotype in 62--67% of cases is promising regarding the potential of CE-FDG PET/MR to non-invasively assess whole-tumour phenotypes.
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![**ER and/or PR and PET/MR biomarkers. Diagram displaying the correlation between ER and/or PR expression and Kep** (**A**). Diagram displaying the correlation between ER and/or PR expression and SUV~max~ (**B**). ER+ and PR+ cancer: a high-resolution contrast-enhanced axial T1w VIBE (**C**) is shown with the corresponding axial Kep parametric map (**D**) and axial PET image (**E**). ER− and PR− cancer: a perfusion subtracted MRI (**F**) is shown with the corresponding parametric axial Kep parametric map (**G**) and axial PET image (**H**). The ER+ and PR+ cancer (arrow) is well depicted after contrast (**C**) and shows an extremely low Kep value, as demonstrated by the black colour (**D**). In Kep parametric maps, low values are displayed by dark colours (from black to dark tones of blue), meanwhile high Kep values are presented in light colours (from lighter tones of blues, to green and then yellow). The cancer also takes up low amounts of FDG (**E**). The ER− and PR− cancer (arrow) markedly enhances after contrast administration (**F**) and exhibits higher Kep values (**G**), as demonstrated by the light blue to green colour in the Kep parametric map. FDG uptake is pronounced (**H**).](bjc201726f1){#fig1}

![**Her2 and PET/MR biomarkers. Diagram demonstrating correlation between Her2 expression and Kep**(**A**); diagram showing correlation between Her2 expression and ADC (**B**); diagram displaying correlation between Her2 expression and SUV~max~ (**C**). Her2+ cancer (**D**--**F**). A Kep parametric map (**D**) is shown with a corresponding ADC map (**E**) and axial PET (**F**). The Her2+ cancer (arrow) demonstrates high Kep values (light blue) (**D**), low ADC values (dark grey) (**E**), and high FDG uptake (**F**). Her2− cancer (**G**--**I**). A Kep parametric map (**G**) is shown with a corresponding ADC map (**H**) and axial PET (**I**). Her2− cancer displays low Kep values (dark blue) (**G**), high ADC values (light gray) (**F**), and low FDG uptake (**I**).](bjc201726f2){#fig2}

![**Ki67 and PET/MR biomarkers.**Diagram displaying correlation between expression of Ki67 and ADC ~mean~ (**A**). Ki67− cancer (**B** and **C**). Axial high-resolution contrast-enhanced MRI (**B**) is shown with a corresponding ADC map (**C**). The Ki67− cancer (arrow) demonstrates low values on the ADC map (**C**). Ki67+ cancer (**D** and **E**). An axial high-resolution contrast-enhanced MRI (**D**) is shown with a corresponding ADC map (**E**). The Ki67+ cancer (arrow) exhibits higher ADC values (**E**).](bjc201726f3){#fig3}

###### Technical details of the examination

                                                                        **MR**                                                                                                                                       
  --------------------------------------------------------------------- --------- ------------ --- ------ -------------------------- ----------- --- ----------- ----- ----- --------------------- ----------------- --------
  Whole-body T1w 2-Point Dixon VIBE (for attenuation correction only)   Coronal   Whole body    2   3.6    1st TE 1.225 2nd TE 2.45   79 × 192    1      500      3.1    0           10^0^          4.1 × 2.6 × 3.1  None
  Breast DWI                                                            Axial     Breast        2   9600              74              78 × 192    3      340       4    0.8                          1.8 × 1.8 × 4   Strong
  Breast VIBE (MR perfusion)                                            Axial     Breast        2   5.3              1.7              130 × 192   6   356 × 380   3.6    0    2, 5, 8, 12, 15, 20   2.3 × 1.7 × 3.6  None

          **PET**                                                
  ------ --------- ------------ --- ---- ----- ----------------- -----------
  5--6       4      AW OSEM 3D   3   21   258   2.0 × 2.0 × 2.0   172 × 172

Abbreviations: AW OSEM 3D=3-dimensional attenuation weighted ordered subsets expectation maximisation iterative reconstruction algorithm; BP=bed position; DWI=diffusion weighted imaging; FA=flip angle; FOV=field of view; FS=fat saturated; GE=gradient echo; iPat=integrated parallel acquisition technique; MR=magnetic resonance; PET=positron emission tomography; SPAIR=spectral adiabatic inversion recovery; TE=time of echo; TI=time of inversion; TR=time of repetition; VIBE=volume interpolated breath hold T1 weighted.

For the whole-body PET/MR, PET data underwent automatic attenuation correction using attenuation maps generated from the 2-point Dixon sequence.

Whole-PET/MR pertinent technical details are given in the above table.

###### Receptor status and phenotype based on biopsy in 21 cases, on whole-mastectomy specimen in 16 cases, and on the combination of whole-mastectomy specimen and biopsy

                **Receptor status**                                                
  ------------ --------------------- ------ ------- ------ ------- ------- ------- ------
  Biopsy               14/21          7/21   12/21   9/21   10/21   11/21   12/21   9/21
  Mastectomy           11/16          5/16   9/16    7/16   6/16    10/16   10/16   6/16

                            **Phenotype**                
  ------------------------ --------------- ------ ------ ------
  Biopsy                        3/21        8/21   3/21   7/21
  Mastectomy                    5/16        5/16   1/16   5/16
  Biopsy plus Mastectomy        6/21        5/21   3/21   7/21

Abbreviations: ER=oestrogen receptor expression; HER2=human epidermal growth factor receptor 2; PR=progesterone receptor expression; Ki67=antigen Ki-67.

###### Schematic of PET/MR biomarkers according to receptor status and grading

                                  **ER/PR−**     **ER or PR+**   ***P*****-value**     **HER2−**        **HER2+**     ***P*****-value**         **Ki67⩽14%**                 **Ki67\>14%**          ***P*****-value**      **G2**           **G3**       ***P*****-value**
  ---------------------------- ---------------- --------------- ------------------- ---------------- --------------- ------------------- --------------------------- ----------------------------- ------------------- --------------- ---------------- -------------------
  Kep~mean~(min−1)              **9234±1320**    **6492±2359**       **0.011**       **8599±2122**    **6322±2241**       **0.028**               6974±2652                    7622±2380                  0.577         **6638±2392**   **8944±1765**        **0.036**
  ADC~mean~(× 10^−6^mm^2^/s)       1275±130        1096±288            0.139          **1303±121**    **1022±280**        **0.009**       **964±242** **904±240\***   **1252±214** **1216±230\***       **0.025**         1099±290         1268±131            0.633
  SUV~max~                      **14.19±7.17**   **6.18±4.34**       **0.005**       **11.79±7.65**   **6.17±4.02**       **0.046**               5.9±4.97                    10.31±6.88                  0.149         **6.83±4.73**   **12.89±8.08**       **0.042**

Abbreviations: ADC=apparent diffusion coefficient; ER=oestrogen receptor expression; HER2=human epidermal growth factor receptor 2; MR=magnetic resonance; PET=positron emission tomography; PR=progesterone receptor expression; Ki67=antigen Ki-67.

ER, PR, and HER2 expression was concordant on whole-mastectomy assessment and biopsy. Different expression of Ki67 was encountered between whole-mastectomy specimen and biopsy, therefore the latter has been indicated by \*.

Statistically significant results are in bold.

###### Schematics of prediction of breast cancer phenotypes from Kep~mean~+ADC~mean~+SUV~max~

                                                                        **Predicted**          **Leave-one-out cross validation**                                          
  -------------------------------------------------------------- ---------------------------- ------------------------------------ ------- ------- ------- ------- ------- -------
  **Results on biopsy Only**                                                                                                                                               
  Observed                                                                                                                                                                     
   HER2 enriched                                                            **5**                              0                      0       2     **4**     0       0       3
   Luminal A                                                                  0                              **2**                    1       0       0     **0**     3       0
   Luminal B                                                                  1                                0                    **6**     1       1       2     **4**     1
   Luminal HER2                                                               1                                0                      1     **1**     1       0       2     **0**
                                                                  **14/21** (67%); *P*=0.004        **8/21** (38%); *P*=0.22                                               
  **Results on mastectomy in 16 cases plus biopsy in 5 cases**                                                                                                             
  Observed                                                                                                                                                                     
   HER2 enriched                                                            **6**                              0                      0       1     **5**     0       0       2
   Luminal A                                                                  1                              **5**                    0       0       1     **4**     1       0
   Luminal B                                                                  1                                2                    **1**     1       1       2     **1**     1
   Luminal HER2                                                               1                                0                      1     **1**     1       0       2     **0**
                                                                  **13/21** (62%); *P*=0.001       **10/21** (48%); *P*=0.04                                               

Abbreviations: ADC=apparent diffusion coefficient; HER2=human epidermal growth factor receptor 2.
